ALVO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 16:00):
Our systems believe the stock currently is overvalued by -0.81% compare to its pairs and should correct downwards.

Stats
Today's Volume	166 670
Average Volume	182 962
Market Cap	3.40B
EPS	$-0.820 ( Q1 \| 2024-03-31 )
Next earnings date	( $-0.280 ) 2024-09-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.85 (Sector) 42.63 (Industry) 30.78
ATR14	$0.00700 (0.06%)

AERI 0.00%

ALVO 1.33%

ALVOW 6.79%

BDSI -0.09%

BFRIW -5.93%

CLVRW 0.00%

CYTHW -4.35%

ENDP 0.00%

GRVI 7.61%

HPCO 0.06%

INDV -1.59%

JUPWW -20.00%

LFCR -0.19%

LNDC -3.52%

LSDI -23.29%

PRFX -3.65%

PROCW 10.09%

QLI 6.82%

SBFMW 0.00%

SHOT 9.43%

SHPH 4.28%

Correlation (AI algo v.1.1b): Overvalued: -0.81% $12.23 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.27 (neutral)

Short: 0.44 (neutral)

Signal:(77.508) Neutral

Alvotech Correlation

10 Most Positive Correlations
OZEM	1
NUVO	0.806

10 Most Negative Correlations
BKHA	-0.981
RFAIU	-0.915
PSTR	-0.881
ERNZ	-0.854
BKHAR	-0.832
INDH	-0.831
IBAC	-0.822
AGMI	-0.811
LENZ	-0.807

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alvotech Correlation - Currency/Commodity

-0.33
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.42
( neutral )

0.62
( weak )

0.63
( weak )

Alvotech Financials

Annual	2023
Revenue:	$91.43M
Gross Profit:	$-69.42M (-75.93 %)
EPS:	$-2.43

FY	2023
Revenue:	$91.43M
Gross Profit:	$-69.42M (-75.93 %)
EPS:	$-2.43

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

FY	2022
Revenue:	$83.03M
Gross Profit:	$18.93M (22.80 %)
EPS:	$-2.60

Financial Reports:

No articles found.

Alvotech Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company\'s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn\'s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn\'s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.